Valuation: Zai Lab Limited

Market Cap 293.8Cr 251.76Cr 235.9Cr 215.48Cr 406.66Cr 28TCr 410.67Cr 2.78TCr 1.08TCr 14TCr 1.1TCr 1.08TCr 47TCr P/E 2026 *
-11.6x
P/E 2027 * -12.2x
Enterprise Value 248.04Cr 212.54Cr 199.16Cr 181.92Cr 343.32Cr 24TCr 346.7Cr 2.35TCr 914.51Cr 12TCr 931.32Cr 911.03Cr 40TCr EV / Sales 2026 *
5.87x
EV / Sales 2027 * 4.5x
Free-Float
94.05%
Yield 2026 *
-
Yield 2027 * -
1 week+1.82%
Current month+41.77%
1 month+32.54%
3 months+44.52%
6 months+36.59%
Current year+51.35%
1 week 20.6
Extreme 20.6
23
1 month 15.5
Extreme 15.5
23
3 years 12.6
Extreme 12.6
38.2
5 years 12.6
Extreme 12.6
127
Manager TitleAgeSince
Chief Executive Officer 61 01/04/2014
Director of Finance/CFO 58 07/07/2023
President 62 01/12/2022
Director TitleAgeSince
Chairman 61 01/04/2014
Director/Board Member 83 01/01/2017
Director/Board Member 75 01/01/2017
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+1.82%-23.29%+1.82% 293.8Cr
+0.61%+2.88%+45.63%+0.39% 8.32TCr
-0.23%+3.99%-19.54%-35.39% 5.95TCr
+14.36%+152.27%+526.55%+41.90% 6.34TCr
+0.76%+3.53%+0.08%+36.18% 5.29TCr
+1.86%+3.13%+11.49%+174.36% 4.99TCr
+1.21%+3.87%+61.90%-16.51% 3.26TCr
+1.36%+5.06%+53.04%+103.13% 2.63TCr
+9.39%+11.15%+14.05%+214.24% 2.22TCr
+3.89%+1.08%+61.82%+112.10% 1.72TCr
Average +3.65%+20.50%+73.17%+63.22% 4.53TCr
Weighted average by Cap. +3.49%+27.36%+100.73%+48.91%

Financials

2026 *2027 *
Net sales 42Cr 36Cr 34Cr 31Cr 58Cr 4.03TCr 59Cr 400.28Cr 155.83Cr 2.03TCr 158.69Cr 155.24Cr 6.73TCr 57Cr 49Cr 46Cr 42Cr 79Cr 5.42TCr 80Cr 538.79Cr 209.75Cr 2.74TCr 213.6Cr 208.95Cr 9.06TCr
Net income -25Cr -21Cr -20Cr -18Cr -34Cr -2.34TCr -34Cr -232.09Cr -90Cr -1.18TCr -92Cr -90Cr -3.9TCr -19Cr -16Cr -15Cr -14Cr -26Cr -1.78TCr -26Cr -177.02Cr -69Cr -899.02Cr -70Cr -69Cr -2.98TCr
Net Debt -46Cr -39Cr -37Cr -34Cr -63Cr -4.36TCr -64Cr -433.45Cr -168.74Cr -2.2TCr -171.84Cr -168.1Cr -7.29TCr -38Cr -33Cr -31Cr -28Cr -53Cr -3.63TCr -53Cr -360.67Cr -140.41Cr -1.83TCr -142.99Cr -139.87Cr -6.07TCr
Logo Zai Lab Limited
Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets.
Employees
-
Date Price Change
26/26/26 22.40 +8.74%
24/26/24 €20.60 -7.21%
21/26/21 €22.20 0.00%
20/26/20 €22.20 -2.63%
19/26/19 €22.80 +3.64%
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
26.17USD
Average target price
32.39USD
Spread / Average Target
+23.77%

Quarterly revenue - Rate of surprise